Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
Top Recent PubMed Articles
99 results
  • Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. [Journal Article]
  • NEJMN Engl J Med 2018 Dec 05
  • von Minckwitz G, Huang CS, … KATHERINE Investigators
  • CONCLUSIONS: Among patients with HER2-positive early breast cancer who had residual invasive disease after completion of neoadjuvant therapy, the risk of recurrence of invasive breast cancer or death was 50% lower with adjuvant T-DM1 than with trastuzumab alone. (Funded by F. Hoffmann-La Roche/Genentech; KATHERINE number, NCT01772472 .).
  • Pericardium in Reconstructive Urologic Surgeries: A Systematic Review and Meta-Analysis. [Review]
  • UIUrol Int 2018 Dec 05; :1-14
  • Hosseini J, Hosseini S, … Rezaei Y
  • CONCLUSIONS: Our systematic review demonstrates the feasibility of the pericardium, regardless of its type, in urologic surgeries. It, however, seems that urethral substitution needs further investigation. Given the lower cost, easier handling, and less immunogenicity of the pericardium, further studies are required to examine its pros and cons.
  • Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. [Journal Article]
  • NEJMN Engl J Med 2018 Dec 04
  • Carrier M, Abou-Nassar K, … AVERT Investigators
  • CONCLUSIONS: Apixaban therapy resulted in a significantly lower rate of venous thromboembolism than did placebo among intermediate-to-high-risk ambulatory patients with cancer who were starting chemotherapy. The rate of major bleeding episodes was higher with apixaban than with placebo. (Funded by the Canadian Institutes of Health Research and Bristol-Myers Squibb-Pfizer Alliance; AVERT number, NCT02048865 .).
  • Changes in health in the countries of the UK and 150 English Local Authority areas 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. [Journal Article]
  • LctLancet 2018 Nov 03; 392(10158):1647-1661
  • Steel N, Ford JA, … Murray CJL
  • CONCLUSIONS: These estimates at local, regional, and national level will allow policy makers to match resources and priorities to levels of burden and risk factors. Improvement in YLLs and life expectancy slowed notably after 2010, particularly in cardiovascular disease and cancer, and targeted actions are needed if the rate of improvement is to recover. A targeted policy response is also required to address the increasing proportion of burden due to morbidity, such as musculoskeletal problems and depression. Improving the quality and completeness of available data on these causes is an essential component of this response.
New Search Next